The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Use a concentration of 0.5 - 1 µg/ml. Predicted molecular weight: 6.2 kDa. Used in conjunction with compatible secondary reagents the detection limit for recombinant Rat EGF is 1.5 - 3.0 ng/lane, under either reducing or non-reducing conditions.
Use a concentration of 0.1 µg/ml. to yield one-half maximal inhibition [ND50] of the biological activity of Rat EGF (0.1 ng/ml).
Use a concentration of 0.5 - 2 µg/ml. In conjunction with compatible secondary reagents, ab77851 allows the detection of at least 0.2 - 0.4 ng/well of recombinant Rat EGF.
Use a concentration of 0.5 - 2 µg/ml.
Use at an assay dependent concentration. PubMed: 21121876
Use a concentration of 1 µg/ml.
FunctionEGF stimulates the growth of various epidermal and epithelial tissues in vivo and in vitro and of some fibroblasts in cell culture. Magnesiotropic hormone that stimulates magnesium reabsorption in the renal distal convoluted tubule via engagement of EGFR and activation of the magnesium channel TRPM6. Can induce neurite outgrowth in motoneurons of the pond snail Lymnaea stagnalis in vitro (PubMed:10964941).
Tissue specificityExpressed in kidney, salivary gland, cerebrum and prostate.
Involvement in diseaseHypomagnesemia 4
Sequence similaritiesContains 9 EGF-like domains. Contains 9 LDL-receptor class B repeats.
Post-translational modificationsO-glycosylated with core 1-like and core 2-like glycans. It is uncertain if Ser-954 or Thr-955 is O-glycosylated. The modification here shows glycan heterogeneity: HexHexNAc (major) and Hex2HexNAc2 (minor).
Li H et al. Different expression patterns of growth factors in rat fetuses with spina bifida aperta after in utero mesenchymal stromal cell transplantation. Cytotherapy16:319-30 (2014).
Read more (PubMed: 24364908) »
Williams CM et al. Autocrine-controlled formation and function of tissue-like aggregates by primary hepatocytes in micropatterned hydrogel arrays. Tissue Eng Part A17:1055-68 (2011).
Read more (PubMed: 21121876) »